Table 4.

Relationship between SHOX2 and RASSF1A methylation and clinicopathological characteristics in patients with lung adenocarcinoma

Clinicopathological index	n = 238	SHOX2 positive [n (%)] n = 108	P	RASSF1A positive [n (%)] n = 98	P	LungMe® positive [n (%)] n = 142	P
Age (Years)			< 0.001*		0.062		0.011*
<65	116	37(31.9)		42(36.2)		60 (51.7)
≥ 65	122	71(58.2)		56(45.9)		82(67.2)
Gender			< 0.001*		0.004*		0.001*
Male	82	50(61.0)		44(53.7)		63(76.8)
Female	156	58(37.2)		54(34.6)		79(50.6)
Tumor imaging features			0.003*		0.005*		0.001*
Pure GGO	40	13(32.5)		12(30.0)		19(47.5)
Mixed GGO	136	56(41.2)		50(36.8)		74(54.4)
Solid	62	39(62.9)		36(58.1)		49(79.0)
Tumor size			< 0.001*		< 0.001*		< 0.001*
≤ 1 cm	59	13(22.0)		10(16.9)		18(30.5)
>1,≤3 cm	162	82(50.6)		76(46.9)		109(67.3)
>3 cm	14	12(85.7)		11(78.6)		13(92.9)
TNM stage			< 0.001*		< 0.001*		< 0.001*
T0 stage	31	3(9.7)		4(12.9)		5(16.1)
IA stage	186	90(48.4)		80(43.0)		119(64.0)
IB stage	11	10(90.9)		10(90.9)		11(100)
II ~ IV stage	10	5(50.0)		4(40.0)		7(70.0)
Pathological type			< 0.001*		< 0.001*		< 0.001*
AIS	31	3(9.7)		4(12.9)		5(16.1)
MIA	36	11(30.6)		8(22.2)		15(41.7)
IA	171	94(55.0)		86(50.3)		122(71.3)
IA WHO subtype			0.175		0.251		0.026*
I grade	23	9(39.1)		10(43.5)		12(52.2)
II grade	120	59(49.2)		65(54.2)		85(70.8)
III grade	16	11(68.8)		11(68.8)		15(93.8)
Pleural invasion			0.001*		0.008*		< 0.001*
No	210	88(41.9)		81(38.6)		118(56.2)
Yes	26	20(76.9)		17(65.4)		24(92.3)
STAS			0.031*		0.110		0.044*
No	218	96(44.0)		88(40.4)		128(58.7)
Yes	17	12(70.6)		10(58.8)		14(82.4)
Lymphnode metastasis			0.276		0.565		0.312
No	227	103(45.4)		94(41.4)		135(59.5)
Yes	8	5(62.5)		3(37.5)		6(75.0)

Note LungMe® is a combination of SHOX2 and RASSF1A methylation

GGO: ground-glass opacity; AIS: Adenocarcinoma in situ; MIA: Microinvasive adenocarcinoma; IA: Invasive adenocarcinoma; IMA: Invasive mucinous adenocarcinoma; STAS: spread through air space